CKD Screening

en-uae
- en-uae
- en-sa
- en-kw
- en-qa
- en-bh
- en-om

Home
CVRM
Oncology
Hematology
Respiratory
Biologics
Vaccine & Immunology
Rare Disease
AZ-Week/Value
AZ Spotlight 2024
Care Corner
Gastrointestinal
Resources-backup-24-04-2019
Live Events
Recorded Videos
COVID-19 updates
Recorded Videos
Pharmacist
Patient Centricity
AZ-World Disease day
Educational Hub
Pharmacist
Pharmacist
Care Corner Backup

More Hide
en-uae
- en-uae
- en-sa
- en-kw
- en-qa
- en-bh
- en-om

Know your Patient’s risk
for Kidney Disease?

Find out if your patients might have silent chronic kidney disease now. Please note that this is not intended to replace the advice of a healthcare professional. Always consult doctor.

Take Survey

What is CKD?

Chronic Kidney Disease also known as CKD is a condition where the kidneys get damaged and can no longer filter blood the way that they should. This means toxins start building up in the body. If not detected in time, CKD can be fatal.

Configure Image Component

Screening
for CKD

It is recommended that screening in adults with CKD or at risk for CKD be done by testing for albuminuria. Albumin-to-creatinine ratio (ACR) is the first method of preference to detect elevated protein. The recommended method to evaluate albuminuria is to measure urinary ACR in a spot urine sample.

iFrameDescription

Y1-1037

Modal Window Component Section Begins

Modal Window Component Section Ends

Thank you for visiting the AstraZeneca Medicines website

This link will take you to a website not owned by AstraZeneca. AstraZeneca provides this link as a service to our site visitors. AstraZeneca are not responsible for the content or privacy / legal policies of any third party websites.

Do you wish to continue?

Cancel Continue

Thank you for visiting the AstraZeneca Medicines website

Do you wish to continue?

Cancel Continue

AstraZeneca EduGate

This website is intended for doctors, nurses, and pharmacists in UAE. If Other please visit www.astrazeneca.com.

Additional Info

Legal Notice and Terms of Use
Privacy Notice
Cookie Policy

Contact AstraZeneca

Contact Us
Report Adverse Event

Adverse events should be reported. Reporting forms and information can be found at aereporting.astrazeneca.com. Adverse events in the rest of the Gulf Countries (UAE, Bahrain, Qatar, Oman and Kuwait) should also be reported to AstraZeneca Gulf on +97143624888 / email at patientsafety-azgulf@astrazeneca.com

Approval Code: SA-2772 / Y1-1123

For Medical information Enquires
Website: https://contactazmedical.astrazeneca.com
E-mail: gulf-medicalinfo@astrazeneca.com
Tel: +971 43624888

Configure Footer Reference Component

Reference